CYTOKINETICS INC (CYTK)
$73.00-$4.90 (-6.29%) Today
Andrew Callos - OfficerCytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 15 | 88,246 | $7.10M |
| Grant or award | 6 | 875 | |
| Option exercise | 32 | 146,472 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
191 Form 4 filings on record, the earliest from Oct 1, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Fady Ibraham Malik - Officer | Option exercise | Common Stock | 3,500 | $7.80 | $27K | |
| Fady Ibraham Malik - Officer | Open-market sale | Common Stock | 3,500 | $75.82 | $265K | |
| Fady Ibraham Malik - Officer | Option exercise | Non-Qualified Stock Option (Right to Buy) | 3,500 | $0.00 | - | |
| Robert I. Blum - Officer | Option exercise | Common Stock | 7,500 | $10.60 | $80K | |
| Robert I. Blum - Officer | Open-market sale | Common Stock | 7,500 | $76.76 | $576K | |
| Robert I. Blum - Officer | Option exercise | Non-Qualified Stock Option (Right to Buy) | 7,500 | $0.00 | - | |
| Andrew Callos - Officer | Option exercise | Common Stock | 14,000 | $23.26 | $326K | |
| Andrew Callos - Officer | Open-market sale | Common Stock | 14,000 | $79.88 | $1.12M | |
| Andrew Callos - Officer | Option exercise | Non-Qualified Stock Option (Right to Buy) | 14,000 | $0.00 | - | |
| Robert I. Blum - Officer | Option exercise | Common Stock | 7,500 | $10.60 | $80K | |
| Robert I. Blum - Officer | Open-market sale | Common Stock | 7,500 | $80.87 | $607K | |
| Robert I. Blum - Officer | Option exercise | Non-Qualified Stock Option (Right to Buy) | 7,500 | $0.00 | - | |
| Fady Ibraham Malik - Officer | Option exercise | Common Stock | 3,500 | $7.80 | $27K | |
| Fady Ibraham Malik - Officer | Open-market sale | Common Stock | 3,500 | $80.59 | $282K | |
| Fady Ibraham Malik - Officer | Option exercise | Non-Qualified Stock Option (Right to Buy) | 3,500 | $0.00 | - | |
 Nancy Wysenski - Director | Grant or award | Common Stock | 75 | $82.62 | $6K | |
| Wendell Wierenga - Director | Grant or award | Common Stock | 75 | $82.62 | $6K | |
 Edward M. Md Kaye - Director | Grant or award | Common Stock | 151 | $82.62 | $12K | |
| John T. Henderson - Director | Grant or award | Common Stock | 272 | $82.62 | $22K | |
| Robert Arthur Harrington - Director | Grant or award | Common Stock | 151 | $82.62 | $12K | |
| James M. Daly - Director | Grant or award | Common Stock | 151 | $82.62 | $12K | |
| Robert I. Blum - Officer | Open-market sale | Common Stock | 10 | $82.02 | $820 | |
| Robert I. Blum - Officer | Option exercise | Common Stock | 7,490 | $10.60 | $79K | |
| Robert I. Blum - Officer | Open-market sale | Common Stock | 7,490 | $82.02 | $614K | |
| Robert I. Blum - Officer | Option exercise | Non-Qualified Stock Option (Right to Buy) | 7,490 | $0.00 | - | |
| Fady Ibraham Malik - Officer | Option exercise | Common Stock | 3,500 | $7.80 | $27K | |
| Fady Ibraham Malik - Officer | Open-market sale | Common Stock | 3,500 | $86.62 | $303K | |
| Fady Ibraham Malik - Officer | Option exercise | Non-Qualified Stock Option (Right to Buy) | 3,500 | $0.00 | - | |
| Robert I. Blum - Officer | Open-market sale | Common Stock | 7,500 | $84.92 | $637K | |
| Andrew Callos - Officer | Option exercise | Common Stock | 15,000 | $23.26 | $349K | |
| Andrew Callos - Officer | Open-market sale | Common Stock | 15,000 | $85.80 | $1.29M | |
| Andrew Callos - Officer | Option exercise | Non-Qualified Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Sung Lee - Officer | Option exercise | Common Stock | 1,112 | $48.51 | $54K | |
| Sung Lee - Officer | Open-market sale | Common Stock | 1,112 | $87.79 | $98K | |
| Sung Lee - Officer | Option exercise | Non-Qualified Stock Option (Right to Buy) | 1,112 | $0.00 | - | |
| Sung Lee - Officer | Option exercise | Common Stock | 1,113 | $48.51 | $54K | |
| Sung Lee - Officer | Option exercise | Common Stock | 823 | $44.36 | $37K | |
| Sung Lee - Officer | Open-market sale | Common Stock | 3,134 | $85.00 | $266K | |
| Sung Lee - Officer | Option exercise | Incentive Stock Option (Right to Buy) | 188 | $0.00 | - | |
| Sung Lee - Officer | Option exercise | Incentive Stock Option (Right to Buy) | 188 | $0.00 | - | |
| Sung Lee - Officer | Option exercise | Non-Qualified Stock Option (Right to Buy) | 822 | $0.00 | - | |
| Sung Lee - Officer | Option exercise | Non-Qualified Stock Option (Right to Buy) | 1,113 | $0.00 | - | |
| Sung Lee - Officer | Option exercise | Non-Qualified Stock Option (Right to Buy) | 823 | $0.00 | - | |
| Sung Lee - Officer | Option exercise | Common Stock | 188 | $44.36 | $8K | |
| Sung Lee - Officer | Option exercise | Common Stock | 188 | $44.36 | $8K | |
| Sung Lee - Officer | Option exercise | Common Stock | 822 | $44.36 | $36K | |
| Fady Ibraham Malik - Officer | Option exercise | Common Stock | 3,500 | $7.80 | $27K | |
| Fady Ibraham Malik - Officer | Open-market sale | Common Stock | 3,500 | $79.51 | $278K | |
| Fady Ibraham Malik - Officer | Option exercise | Non-Qualified Stock Option (Right to Buy) | 3,500 | $0.00 | - | |
| Robert I. Blum - Officer | Open-market sale | Common Stock | 7,500 | $70.46 | $528K | |
| Fady Ibraham Malik - Officer | Option exercise | Common Stock | 3,500 | $7.80 | $27K | |
| Fady Ibraham Malik - Officer | Open-market sale | Common Stock | 3,500 | $67.98 | $238K | |
| Fady Ibraham Malik - Officer | Option exercise | Non-Qualified Stock Option (Right to Buy) | 3,500 | $0.00 | - | |
| Edward M. Md Kaye - Director | Open-market sale | Common Stock | 2,933 | $76.09 | $223K | |
| Andrew Callos - Officer | Option exercise | Common Stock | 15,000 | $23.26 | $349K | |
| Andrew Callos - Officer | Open-market sale | Common Stock | 15,000 | $74.08 | $1.11M | |
| Andrew Callos - Officer | Option exercise | Non-Qualified Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
 B. Lynne Parshall - Director | Open-market sale | Common Stock | 5,000 | $74.08 | $370K | |
| Robert I. Blum - Officer | Open-market sale | Common Stock | 7,500 | $77.21 | $579K | |
 Muna Bhanji - Director | Grant or award | Common Stock | 2,851 | $0.00 | - | |
| Muna Bhanji - Director | Grant or award | Non-Qualified Stock Option (Right to Buy) | 4,301 | $0.00 | - | |
| James M. Daly - Director | Grant or award | Common Stock | 2,851 | $0.00 | - | |
| James M. Daly - Director | Grant or award | Non-Qualified Stock Option (Right to Buy) | 4,301 | $0.00 | - | |
| Robert Arthur Harrington - Director | Grant or award | Common Stock | 2,851 | $0.00 | - | |
| Robert Arthur Harrington - Director | Grant or award | Non-Qualified Stock Option (Right to Buy) | 4,301 | $0.00 | - | |
| John T. Henderson - Director | Grant or award | Common Stock | 2,851 | $0.00 | - | |
| John T. Henderson - Director | Grant or award | Non-Qualified Stock Option (Right to Buy) | 4,301 | $0.00 | - | |
| Edward M. Md Kaye - Director | Grant or award | Common Stock | 2,851 | $0.00 | - | |
| Edward M. Md Kaye - Director | Grant or award | Non-Qualified Stock Option (Right to Buy) | 4,301 | $0.00 | - | |
| B. Lynne Parshall - Director | Grant or award | Common Stock | 2,851 | $0.00 | - | |
| B. Lynne Parshall - Director | Grant or award | Non-Qualified Stock Option (Right to Buy) | 4,301 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
CYTOKINETICS INC (CYTK) had 20 insider filings in the last 90 days, with the most recent on 2026-08-18. The full record for CYTK runs to 191 Form 4 filings, the earliest from 2024-10-01. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of CYTK were filed in the last 90 days.
15 insider sales of CYTK were filed in the last 90 days, totaling $7.10M.
This page tracks CYTK Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add CYTK to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
